Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Apixaban alone Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery

NCT03251482
View directory record Official record
Conditions
VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
Interventions
JNJ-64179375 0.3 mg/kg, JNJ-64179375 0.6 mg/kg, JNJ-64179375 1.2 mg/kg, JNJ-64179375 (Dose to be Determined), JNJ-64179375 A mg/kg, JNJ-64179375 B mg/kg, JNJ-64179375 C mg/kg, JNJ-64179375 D mg/kg, Placebo JNJ-64179375, Apixaban placebo, Apixaban 2.5 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
50 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Phoenix, Arizona • Torrance, California • Englewood, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus

NCT03083782
View directory record Official record
Conditions
Venous Thromboembolism, Pharmacokinetics, Healthy
Interventions
Apixaban alone, Cyclosporine, Tacrolimus, Apixaban
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 5, 2026, 10:05 AM EDT
Terminated No phase listed Observational

Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism Converted From LMWH to Apixaban

NCT04895553
View directory record Official record
Conditions
Glioma, Malignant
Interventions
Observation of ICH and VTE
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Sacramento, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis

NCT01340586
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Sep 5, 2026, 10:05 AM EDT
Recruiting Not applicable Interventional

DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

NCT05701917
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Interventions
ClotTriever System, Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
Device · Drug
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
48
States / cities
Scottsdale, Arizona • Tucson, Arizona • Orange, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT

NCT03288454
View directory record Official record
Conditions
Healthy
Interventions
Ciraparantag, Placebo, Apixaban
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Sep 5, 2026, 10:05 AM EDT
Active, not recruiting Not applicable Interventional

The PEERLESS II Study

NCT06055920
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
FlowTriever System, Anticoagulation Agents
Device · Drug
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
42
States / cities
Birmingham, Alabama • Pasadena, California • Aurora, Colorado + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Apixaban in Nephrotic Syndrome

NCT02599532
View directory record Official record
Conditions
Nephrotic Syndrome, Proteinuria
Interventions
apixaban
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 79 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Results available

Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers

NCT03864406
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Cobicistat, Darunavir/Cobicistat, Rivaroxaban
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules

NCT03509883
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Drug: Apixaban sprinkle capsules, Experimental: Apixaban tablets followed by apixaban sprinkle capsules
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Sep 5, 2026, 10:05 AM EDT
Completed No phase listed Observational Results available

Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare

NCT04681482
View directory record Official record
Conditions
Atrial Fibrillation, Obesity, Anticoagulants
Interventions
Apixaban
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
107,383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 3 Interventional

Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment

NCT05894954
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia, Mild
Interventions
Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care, Lifestyle including diet, exercise, stress management
Dietary Supplement · Combination Product · Behavioral
Lead sponsor
Alzheimer's Prevention and Reversal Project, Inc.
Other
Eligibility
45 Years to 76 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Folsom, California • San Rafael, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers

NCT05995119
View directory record Official record
Conditions
Healthy Volunteers, Fasting, Fed
Interventions
Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®)
Drug
Lead sponsor
TAHO Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Sep 5, 2026, 10:05 AM EDT
Recruiting Phase 2 Interventional

Venous Thromboembolism Prevention in Outpatients With Glioma

NCT05683808
View directory record Official record
Conditions
Glioblastoma, Astrocytoma, Venous Thromboembolism
Interventions
Apixaban
Drug
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 2 Interventional

Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B

NCT06205615
View directory record Official record
Conditions
Wound Bleeding
Interventions
BXP154B, Placebo, Punch Biopsy
Drug · Procedure
Lead sponsor
Bio 54, LLC
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects

NCT02034565
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2016 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Pivotal BE Study of TAH3311 ODF vs ELIQUIS® Tablet Under Fasted Condition in Healthy Volunteers

NCT06689436
View directory record Official record
Conditions
Random Allocation, Intermittent Fasting, Enteral Feeding
Interventions
5 mg Apixaban Oral Dissolving Film (fasting), 5 mg Apixaban Oral Dissolving Film (fed), 5 mg Apixaban Oral Tablet (US RS/RLD), 5 mg Apixaban Oral Tablet (EU product)
Drug
Lead sponsor
TAHO Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

NCT02369653
View directory record Official record
Conditions
Lymphoma, Acute Lymphoblastic Leukemia
Interventions
Apixaban, No systemic anticoagulant prophylaxis
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Year to 17 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
64
States / cities
Phoenix, Arizona • Duarte, California • Loma Linda, California + 56 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers

NCT00914641
View directory record Official record
Conditions
Thrombosis
Interventions
Apixaban IR, Apixaban MR1, Apixaban MR2, Apixaban MR3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 24, 2009 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 1 Interventional

Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder

NCT01707394
View directory record Official record
Conditions
Thromboembolism
Interventions
Apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Day to 18 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
18
States / cities
Little Rock, Arkansas • Orange, California • Hartford, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2021 · Synced Sep 5, 2026, 10:05 AM EDT
Recruiting Phase 3 Interventional

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

NCT04045665
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
51
States / cities
Little Rock, Arkansas • Los Angeles, California • Stanford, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra

NCT02270918
View directory record Official record
Conditions
Thrombosis
Interventions
Kcentra, Apixaban, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Sep 5, 2026, 10:05 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs

NCT06933056
View directory record Official record
Conditions
Platelet Function and Reactivity Tests
Interventions
Sotagliflozin (SOTA) followed by 3 drugs in a random order, Aspirin followed by 3 drugs in a random order, Clopidogrel followed by 3 drugs in a random order, Eliquis followed by 3 drugs in a random order
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants

NCT02912234
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban, Clarithromycin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Sep 5, 2026, 10:05 AM EDT